Targeting a Natural Repair System to Restore Brain Health

Rachel Lenington, chief operating officer of Athira Pharma, discusses the case for targeting the HGF/MET neurotrophic system in neurodegenerative diseases, how its experimental therapy fosgonimeton works, and why its continuing to pursue the therapy despite earlier failures.